progression-free survival

Open Access
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han and Kai Li

Cancer Biology & Medicine October 2024, 21 (10) 951-962; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0423
Open Access
Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial
Shuzhen Lai, Peijing Li, Xiaohui Liu, Guihong Liu, Tieming Xie, Xing Zhang, Xiaoxuan Wang, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Fangxiao Lu, Lei Wang, Fagui Jiang, Caixing Sun, Yuanyuan Chen and Ming Chen

Cancer Biology & Medicine May 2024, 21 (5) 433-444; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0373
You have access
Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy
Fan Kou, Lei Wu, Yan Guo, Bailu Zhang, Baihui Li, Ziqi Huang, Xiubao Ren and Lili Yang

Cancer Biology & Medicine May 2022, 19 (5) 685-695; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0728
You have access
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
Zhichao Liao, Ting Li, Chao Zhang, Xinyue Liu, Ruwei Xing, Sheng Teng, Yun Yang, Gang Zhao, Xu Bai, Jun Zhao and Jilong Yang

Cancer Biology & Medicine May 2020, 17 (2) 501-512; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0397

Main menu

User menu

Search

progression-free survival

Navigate

More Information

For Authors

Journal Services